secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nautilus Biotechnology, Inc. (NAUT)
CIK:        0001808805
Form:       8-K
Filed at:   2024-04-30T23:59:59+00:00
Accession:  0001808805-24-000038
Event type: earnings
Sentiment:  negative
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nautilus Q1 net loss $18.7M vs $15.0M YoY; cash $247.7M
-------------------------------------------------------

- Net loss of $18.7M widened from $15.0M in Q1 2023; no revenue reported.
- Operating expenses $21.6M, up 20% YoY on higher headcount for platform development.
- Cash, equivalents and investments $247.7M as of March 31, 2024.
- CEO cites progress on consumables, assay, instrument and software scale/reproducibility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808805/000180880524000038/0001808805-24-000038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808805/000180880524000038/naut-20240430.htm
  HTML page:      https://secwatch.observer/filing/0001808805-24-000038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer